Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 6Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Mantle-Cell 7Recurrence 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Waldenstrom Macroglobulinemia 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphatic Diseases 1Leukemia, Prolymphocytic 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Neoplasms 1Chromosome 17 deletion 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 1Povidone-Iodine 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Bronchiolitis Obliterans Syndrome × ibrutinib × Clear all
NCT02743546 2025-02-03

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Janssen Research & Development, LLC

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡